title: Apigenin prevents deregulation in the expression pattern of cell-proliferative, apoptotic, inflammatory and angiogenic markers during 7,12-dimethylbenz[a]anthracene-induced hamster buccal pouch carcinogenesis.
abstract: OBJECTIVE
  Malignant tumour arises due to abnormal cell proliferation, chronic inflammation, defect in apoptotic pathway and unwanted angiogenesis. The present study has investigated the modulating effect of apigenin on expression pattern of apoptotic (p53, Bcl-2, Bax, Caspase-3 and 9) cell proliferative (PCNA, Cyclin D1, c-fos), angiogenic (VEGF) and inflammatory (NFκB, COX-2) markers during 7,12-dimethylbenz[a]anthracene (DMBA)-induced hamster buccal pouch carcinogenesis.
  
  
  METHODS
  Oral squamous cell carcinoma was developed in the buccal pouches of golden Syrian hamsters by painting with 0.5% DMBA three times a week for 14 weeks. Deregulation in the expression of the cell proliferation, apoptosis, inflammation and angiogenesis markers was noticed in hamsters treated with DMBA alone.
  
  
  RESULTS
  Oral administration of apigenin at a dose of 2.5mg/kgbw prevented the deregulation of the above mentioned molecular markers in hamsters treated with DMBA.
  
  
  CONCLUSIONS
  Our results thus suggest that apigenin exhibited anti-cell proliferative, anti-inflammatory, anti-angiogenic and apoptotic potential during DMBA-induced hamster buccal pouch carcinogenesis.
authors: Department of Biochemistry and Biotechnology, Faculty of Science, Annamalai University, Annamalainagar, Tamil Nadu 608 002, India.
authors: Simon
authors: S
authors: Silvan
authors: Shanmugam
authors: S
authors: Manoharan
mesh_terms: D015127:9,10-Dimethyl-1,2-benzanthracene / Q000009:adverse effects*; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D042501:Angiogenic Proteins / Q000032:analysis*; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D016588:Anticarcinogenic Agents / Q000627:therapeutic use*; D047310:Apigenin / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects*; D002273:Carcinogens / Q000494:pharmacology*; D002294:Carcinoma, Squamous Cell / Q000139:chemically induced* / Q000473:pathology; D053148:Caspase 3 / Q000187:drug effects; D053453:Caspase 9 / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D006224:Cricetinae; D019938:Cyclin D1 / Q000187:drug effects; D051546:Cyclooxygenase 2 / Q000187:drug effects; D018836:Inflammation Mediators / Q000032:analysis*; D008297:Male; D008647:Mesocricetus; D009062:Mouth Neoplasms / Q000139:chemically induced* / Q000473:pathology; D016328:NF-kappa B / Q000187:drug effects; D018809:Proliferating Cell Nuclear Antigen / Q000187:drug effects; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000187:drug effects; D016760:Proto-Oncogene Proteins c-fos / Q000187:drug effects; D016159:Tumor Suppressor Protein p53 / Q000187:drug effects; D042461:Vascular Endothelial Growth Factor A / Q000187:drug effects; D051028:bcl-2-Associated X Protein / Q000187:drug effects
chemical_list: D020533:Angiogenesis Inhibitors; D042501:Angiogenic Proteins; D000893:Anti-Inflammatory Agents; D016588:Anticarcinogenic Agents; D002273:Carcinogens; D018836:Inflammation Mediators; D016328:NF-kappa B; D018809:Proliferating Cell Nuclear Antigen; D019253:Proto-Oncogene Proteins c-bcl-2; D016760:Proto-Oncogene Proteins c-fos; D016159:Tumor Suppressor Protein p53; D042461:Vascular Endothelial Growth Factor A; D051028:bcl-2-Associated X Protein; D019938:Cyclin D1; D015127:9,10-Dimethyl-1,2-benzanthracene; D047310:Apigenin; D051546:Cyclooxygenase 2; D053148:Caspase 3; D053453:Caspase 9